Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of afatinib plus weekly paclitaxel versus investigator’s choice chemotherapy in NSCLC after TKI failure
2009-014563-39Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: progression-free survival. Started Dec 2009; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-014563-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014563-39.